Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

clostridia strain formulation VE303

An orally bioavailable formulation composed of eight nonpathogenic, nontoxigenic, commensal strains of Clostridia derived from healthy human stool samples and manufactured from clonal cell banks, for the potential prevention of recurrent Clostridium difficile (C. difficile) infections. Upon oral administration of the Clostridia strain formulation VE303, the microbiota populates the gastrointestinal (GI) tract. The transplanted microbiota allows re-population of the patient's microbiome with diverse protective microorganisms that competitively exclude C. difficile. This may prevent recurrent C. difficile infections.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:bacterial strain formulation VE303
live biotherapeutic product VE303
Code name:VE 303
VE-303
VE303
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search